{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:34:29Z","timestamp":1794540869236,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among hematological cancers, Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) are the most common leukemia in children and elderly people respectively. Some patients do not respond to chemotherapy treatments and it is necessary to complement it with immunotherapy-based treatments such as chimeric antigen receptor (CAR) therapy, which is one of the newest and more effective treatments against these cancers and B-cell lymphoma. Although complete remission results are promising, CAR T cell therapy presents still some risks for the patients, including cytokine release syndrome (CRS) and neurotoxicity. We proposed a different immune cell source for CAR therapy that might prevent these side effects while efficiently targeting malignant cells. NK cells from different sources are a promising vehicle for CAR therapy, as they do not cause graft versus host disease (GvHD) in allogenic therapies and they are prompt to attack cancer cells without prior sensitization. We studied the efficacy of NK cells from adult peripheral blood (AB) and umbilical cord blood (CB) against different target cells in order to determine the best source for CAR therapy. AB CAR-NK cells are slightly better at killing CD19 presenting target cells and CB NK cells are easier to stimulate and they have more stable number from donor to donor. We conclude that CAR-NK cells from both sources have their advantages to be an alternative and safer candidate for CAR therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-55239-y","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:03:32Z","timestamp":1575975812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells"],"prefix":"10.1038","volume":"9","author":[{"given":"L.","family":"Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Vesga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-7182","authenticated-orcid":false,"given":"J.","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Martin-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-2077","authenticated-orcid":false,"given":"C.","family":"Eguizabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"55239_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-319-97746-1_8","volume":"1100","author":"I Jeremias","year":"2018","unstructured":"Jeremias, I. & Schewe, D. M. Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1100, 127\u2013139 (2018).","journal-title":"Adv Exp Med Biol."},{"key":"55239_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C Pui","year":"2006","unstructured":"Pui, C. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N Engl J Med. 354, 166\u201378 (2006).","journal-title":"N Engl J Med."},{"key":"55239_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-018-0676-3","volume":"11","author":"Y Zou","year":"2018","unstructured":"Zou, Y., Xu, W. & Li, J. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. J Hematol Oncol. 11, 130 (2018).","journal-title":"J Hematol Oncol."},{"key":"55239_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3109\/10428194.2013.823493","volume":"55","author":"CA Portell","year":"2014","unstructured":"Portell, C. A. & Advani, A. S. Novel targeted therapies in acute lymphoblastic leukemia Novel targeted therapies in acute lymphoblastic leukemia. Leuk Lymphoma. 55, 737\u201348 (2014).","journal-title":"Leuk Lymphoma."},{"key":"55239_CR5","doi-asserted-by":"crossref","unstructured":"Giebel, S. et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in fi rst remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant (2018).","DOI":"10.1038\/s41409-018-0373-4"},{"key":"55239_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19\u2212\/CD3-bispecific single-chain antibody construct. Int J Cancer. 115, 98\u2013104 (2005).","journal-title":"Int J Cancer."},{"key":"55239_CR7","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"AD Kennedy","year":"2004","unstructured":"Kennedy, A. D. et al. rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 172, 3280\u20138 (2004).","journal-title":"J Immunol."},{"key":"55239_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N Engl J Med. 379, 64\u201373 (2018).","journal-title":"N Engl J Med."},{"key":"55239_CR9","first-page":"818","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. Second anticancer CAR T therapy receives FDA approval. Nat Rev Drug Discov. 16, 818 (2017).","journal-title":"Nat Rev Drug Discov."},{"key":"55239_CR10","doi-asserted-by":"crossref","unstructured":"Geyer, M. B. & Brentjens, R. J. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 18, 1393\u20131409 (2016).","DOI":"10.1016\/j.jcyt.2016.07.003"},{"key":"55239_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jcyt.2018.05.001","volume":"20","author":"JM Murad","year":"2018","unstructured":"Murad, J. M. et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor \u2013 expressing T cells for autologous adoptive cell therapy. Cytotherapy. 20, 952\u2013963 (2018).","journal-title":"Cytotherapy."},{"key":"55239_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/02648725.2018.1430465","volume":"33","author":"N Muhammad","year":"2017","unstructured":"Muhammad, N., Mao, Q. & Xia, H. CAR T-cells for cancer therapy. Biotechnol Genet Eng Rev. 33, 190\u2013226 (2017).","journal-title":"Biotechnol Genet Eng Rev."},{"key":"55239_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2012","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor\u2013modified t cells in chronic lymphoid leukemia. N Engl J Med. 365, 725\u201333 (2012).","journal-title":"N Engl J Med."},{"key":"55239_CR14","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2016","unstructured":"Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 125, 4017\u201324 (2016).","journal-title":"Blood."},{"key":"55239_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbmt.2017.10.017","volume":"24","author":"M Perales","year":"2018","unstructured":"Perales, M., Kebriaei, P., Kean, L. S. & Sadelain, M. Biology of Blood and Marrow Transplantation Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. 24, 27\u201331 (2018).","journal-title":"Biol Blood Marrow Transplant."},{"key":"55239_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta, R. S. & Rezvani, K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 9, 1\u201312 (2018).","journal-title":"Front Immunol."},{"key":"55239_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/imt-2016-0127","volume":"9","author":"F Anwer","year":"2017","unstructured":"Anwer, F. et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 9, 123\u201330 (2017).","journal-title":"Immunotherapy."},{"key":"55239_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00195","volume":"6","author":"DL Hermanson","year":"2015","unstructured":"Hermanson, D. L. & Kaufman, D. S. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 6, 1\u20136 (2015).","journal-title":"Front Immunol."},{"key":"55239_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri, M. A. ASH 50th anniversary review Human natural killer cells. Blood. 112, 461\u2013469 (2008).","journal-title":"Blood."},{"key":"55239_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.coi.2004.07.010","volume":"16","author":"L Moretta","year":"2004","unstructured":"Moretta, L. & Moretta, A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 16, 626\u201333 (2004).","journal-title":"Curr Opin Immunol."},{"key":"55239_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","volume":"94","author":"BL Ruggeri","year":"1999","unstructured":"Ruggeri, B. L. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94, 333\u20139 (1999).","journal-title":"Blood."},{"key":"55239_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz, J. E. et al. Journal of clinical oncology nkaml: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 28, 955\u20139 (2010).","journal-title":"J Clin Oncol."},{"key":"55239_CR23","doi-asserted-by":"publisher","first-page":"e0162242","DOI":"10.1371\/journal.pone.0162242","volume":"11","author":"SB Prabhu","year":"2016","unstructured":"Prabhu, S. B., Rathore, D. K., Nair, D., Chaudhary, A. & Raza, S. Comparison of human neonatal and adult blood leukocyte subset composition phenotypes. PLoS One. 11, e0162242, https:\/\/doi.org\/10.1371\/journal.pone.0162242 (2016).","journal-title":"PLoS One."},{"key":"55239_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00755","volume":"8","author":"L Herrera","year":"2017","unstructured":"Herrera, L. et al. OP9 feeder cells are superior to M2-10B4 cells for the generation of mature and functional natural killer cells from umbilical cord hematopoietic progenitors. Front Immunol. 8, 1\u201310 (2017).","journal-title":"Front Immunol."},{"key":"55239_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/15419061.2011.610911","volume":"18","author":"MJ Pinho","year":"2011","unstructured":"Pinho, M. J., Punzel, M., Sousa, M. & Barros, A. Ex vivo differentiation of natural killer cells from human umbilical cord blood CD34 + progenitor cells. Cell Commun Adhes. 18, 45\u201355 (2011).","journal-title":"Cell Commun Adhes."},{"key":"55239_CR26","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","volume":"175","author":"PS Woll","year":"2005","unstructured":"Woll, P. S., Martin, C. H., Miller, J. S. & Dan, S. Functional receptors and cytolytic activity. J Immunol. 175, 5095\u2013103 (2005).","journal-title":"J Immunol."},{"key":"55239_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jcyt.2015.03.611","volume":"17","author":"M Granzin","year":"2015","unstructured":"Granzin, M. et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. J Cytotherapy. 17, 621\u201332 (2015).","journal-title":"J Cytotherapy."},{"key":"55239_CR28","doi-asserted-by":"publisher","first-page":"e20740","DOI":"10.1371\/journal.pone.0020740","volume":"6","author":"J Spanholtz","year":"2011","unstructured":"Spanholtz, J. et al. Clinical-grade generation of active nk cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 6, e20740, https:\/\/doi.org\/10.1371\/journal.pone.0020740 (2011).","journal-title":"PLoS One."},{"key":"55239_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2016.02.003","volume":"177","author":"L Baggio","year":"2017","unstructured":"Baggio, L., Laureano, \u00c1. M., Silla, L. M. D. R. & Lee, D. A. Natural killer cell adoptive immunotherapy: Coming of age. Clin Immunol. 177, 3\u201311 (2017).","journal-title":"Clin Immunol."},{"key":"55239_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu, Y., Tian, Z. & Zhang, C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 39, 167\u2013176 (2018).","journal-title":"Acta Pharmacol Sin."},{"key":"55239_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher, M. & Rezvani, K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 51, 146\u201353 (2018).","journal-title":"Curr Opin Immunol."},{"key":"55239_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","volume":"177","author":"N Shah","year":"2017","unstructured":"Shah, N. et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 177, 457\u2013466 (2017).","journal-title":"Br J Haematol."},{"key":"55239_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani, K. & Rouce, R. H. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 6, 578 (2015).","journal-title":"Front Immunol."},{"key":"55239_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0301-472X(00)00617-2","volume":"29","author":"R Condiotti","year":"2001","unstructured":"Condiotti, R., Bar, Y., Barak, V. & Nagler, A. Ex vivo expansion of CD56 \u03e9 cytotoxic cells from human umbilical cord blood. Exp Hematol. 29, 104\u201313 (2001).","journal-title":"Exp Hematol."},{"key":"55239_CR35","first-page":"1","volume":"0","author":"K Balassa","year":"2017","unstructured":"Balassa, K. & Rocha, V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 0, 1\u201314 (2017).","journal-title":"Expert Opin Biol Ther."},{"key":"55239_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Rivi\u00e8re, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u201398 (2013).","journal-title":"Cancer Discov."},{"key":"55239_CR37","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR \u2013 T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest. 126, 2123\u201338 (2016).","journal-title":"J Clin Invest."},{"key":"55239_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371, 1507\u201317 (2014).","journal-title":"N Engl J Med."},{"key":"55239_CR39","doi-asserted-by":"crossref","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet., Feb 7, 385, 517\u2013528 (2015)","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"55239_CR40","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia. Crit Care Med. 45, e124\u2013e131 (2017).","journal-title":"Crit Care Med."},{"key":"55239_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter, D., Frey, N., Wood, P. A., Weng, Y. & Grupp, S. A. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 11, 35 (2018).","journal-title":"J Hematol Oncol."},{"key":"55239_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.beha.2018.03.001","volume":"31","author":"BJ Mccreedy","year":"2018","unstructured":"Mccreedy, B. J., Senyukov, V. V. & Nguyen, K. T. Best practice & research clinical haematology o ff the shelf T cell therapies for hematologic malignancies. Best Pract Res Clin Haematol. 31, 166\u201375 (2018).","journal-title":"Best Pract Res Clin Haematol."},{"key":"55239_CR43","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1159\/000481946","volume":"40","author":"M Schwarzbich","year":"2017","unstructured":"Schwarzbich, M. & Witzens-harig, M. Cellular immunotherapy in b-cell malignancy. Oncol Res Treat. 40, 674\u2013681 (2017).","journal-title":"Oncol Res Treat."},{"key":"55239_CR44","first-page":"200","volume":"1869","author":"C Lin","year":"2018","unstructured":"Lin, C. & Zhang, J. BBA - Reviews on Cancer Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. BBA - Rev Cancer. 1869, 200\u201315 (2018).","journal-title":"BBA - Rev Cancer."},{"key":"55239_CR45","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann, H. Are natural killer cells superior CAR drivers? Oncoimmunology. 3, e28147 (2014).","journal-title":"Oncoimmunology."},{"key":"55239_CR46","first-page":"248","volume":"73","author":"M Luevano","year":"2012","unstructured":"Luevano, M., Daryouzeh, M., Alnabhan, R., Querol, S. & Khakoo, S. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. HIM. 73, 248\u201357 (2012).","journal-title":"HIM."},{"key":"55239_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","volume":"147","author":"MR Verneris","year":"2009","unstructured":"Verneris, M. R. & Miller, J. S. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 147, 185\u201391 (2009).","journal-title":"Br J Haematol."},{"key":"55239_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1203\/01.PDR.0000156501.55431.20","volume":"57","author":"J Dalle","year":"2005","unstructured":"Dalle, J. et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. May. 57, 649\u201355 (2005).","journal-title":"Pediatr Res. May."},{"key":"55239_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/10826080701690714","volume":"37","author":"Y Fan","year":"2008","unstructured":"Fan, Y., Yang, B. & Wu, C. Phenotypic and functional heterogeneity of natural killer cells from umbilical cord. Immunol Invest. 37, 79\u201396 (2008).","journal-title":"Immunol Invest."},{"key":"55239_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3109\/08880018.2011.613092","volume":"28","author":"S Lin","year":"2011","unstructured":"Lin, S. & Kuo, M. Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy. Pediatr Hematol Oncol. 28, 640\u20136 (2011).","journal-title":"Pediatr Hematol Oncol."},{"key":"55239_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela, M. et al. Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 422, 107\u2013117 (2018).","journal-title":"Cancer Lett."},{"key":"55239_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1034\/j.1600-0609.2003.00081.x","volume":"71","author":"H Tanaka","year":"2003","unstructured":"Tanaka, H. et al. Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood. Eur J Haematol. 71, 29\u201338 (2003).","journal-title":"Eur J Haematol."},{"key":"55239_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1348-0421.1999.tb02387.x","volume":"43","author":"T Hoshina","year":"1999","unstructured":"Hoshina, T., Kida, K. & Ito, M. Difference in response of NK cell activity in newborns and adult to IL-2, IL-12 and IL-15. Microbiol Immunol. 43, 161\u20136 (1999).","journal-title":"Microbiol Immunol."},{"key":"55239_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12026-017-8982-3","volume":"66","author":"R Sharma","year":"2018","unstructured":"Sharma, R. & Das, A. IL-2 mediates NK cell proliferation but not hyperactivity. Immunol Res. 66, 151\u2013157 (2018).","journal-title":"Immunol Res."},{"key":"55239_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1359-6101(01)00021-1","volume":"13","author":"TA Fehniger","year":"2002","unstructured":"Fehniger, T. A., Cooper, M. A. & Caligiuri, M. A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13, 169\u201383 (2002).","journal-title":"Cytokine Growth Factor Rev."},{"key":"55239_CR56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.23736\/S1824-4785.17.03052-7","volume":"62","author":"C Zeelen","year":"2018","unstructured":"Zeelen, C. et al. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy. Q J Nucl Med Mol Imaging. 62, 56\u201377 (2018).","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"55239_CR57","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3748\/wjg.v10.i14.2119","volume":"10","author":"B Peng","year":"2004","unstructured":"Peng, B., Liang, L., He, Q., Huang, J. & Lu, M. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma. World J Gastroenterol. 10, 2119\u201323 (2004).","journal-title":"World J Gastroenterol."},{"key":"55239_CR58","doi-asserted-by":"publisher","first-page":"e53611","DOI":"10.1371\/journal.pone.0053611","volume":"8","author":"O Lim","year":"2013","unstructured":"Lim, O. et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One. 8, e53611, https:\/\/doi.org\/10.1371\/journal.pone.0053611 (2013).","journal-title":"PLoS One."},{"key":"55239_CR59","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","volume":"14","author":"N Lapteva","year":"2012","unstructured":"Lapteva, N. et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 14, 1131\u201343 (2012).","journal-title":"Cytotherapy."},{"key":"55239_CR60","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","volume":"53","author":"L Boissel","year":"2012","unstructured":"Boissel, L. et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 53, 958\u201365 (2012).","journal-title":"Leuk Lymphoma."},{"key":"55239_CR61","doi-asserted-by":"publisher","first-page":"112783","DOI":"10.18632\/oncotarget.22626","volume":"8","author":"KG Pinz","year":"2017","unstructured":"Pinz, K. G. et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 8, 112783\u201396 (2017).","journal-title":"Oncotarget."},{"key":"55239_CR62","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang, X. et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 8, 1083\u20131089 (2018).","journal-title":"Am J Cancer Res."},{"key":"55239_CR63","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 20, 1287\u201394 (2016).","journal-title":"J Cell Mol Med."},{"key":"55239_CR64","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/imt-2017-0022","volume":"9","author":"W Wang","year":"2017","unstructured":"Wang, W., Zhou, G. & Zhang, W. NK-92 cell, another ideal carrier for chimeric antigen receptor. Immunotherapy. 9, 753\u2013765 (2017).","journal-title":"Immunotherapy."},{"key":"55239_CR65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 32, 520\u201331 (2018).","journal-title":"Leukemia."},{"key":"55239_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","volume":"31","author":"R Nair","year":"2018","unstructured":"Nair, R. & Neelapu, S. S. T-cell CAR. Best practice & research clinical haematology The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 31, 293\u20138 (2018).","journal-title":"Best Pract Res Clin Haematol."},{"key":"55239_CR67","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2147\/TCRM.S146309","volume":"14","author":"MH Forsberg","year":"2018","unstructured":"Forsberg, M. H., Das, A. & Christian, M. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Ther Clin Risk Manag. 14, 1573\u20131584 (2018).","journal-title":"Ther Clin Risk Manag."},{"key":"55239_CR68","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ajh.25274","volume":"93","author":"E Jacoby","year":"2018","unstructured":"Jacoby, E. et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol. 93, 1485\u20131492 (2018).","journal-title":"Am J Hematol."},{"key":"55239_CR69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance anti- tumor activity. Cell Stem Cell. 23, 181\u2013192 (2018).","journal-title":"Cell Stem Cell."},{"key":"55239_CR70","first-page":"1","volume":"6","author":"JSH Evert","year":"2017","unstructured":"Evert, J. S. H., Cany, J., Brand, D., Van Den. Oudenampsen, M. & Brock, R. Umbilical cord blood CD34 C progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD\/SCID\/IL2Rg null mice. Oncoimmunology. 6, 1\u201312 (2017).","journal-title":"Oncoimmunology."},{"key":"55239_CR71","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","volume":"23","author":"H Dolstra","year":"2017","unstructured":"Dolstra, H. et al. Successful transfer of umbilical cord blood CD34 \u00fe hematopoietic stem and progenitor- derived nk cells in older acute myeloid leukemia patients. Clin Cancer Res. 23, 4107\u20134118 (2017).","journal-title":"Clin Cancer Res."},{"key":"55239_CR72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131, 861\u201372 (2007).","journal-title":"Cell."},{"key":"55239_CR73","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","volume":"79","author":"H Mollanoori","year":"2018","unstructured":"Mollanoori, H., Shahraki, H., Rahmati, Y. & Teimourian, S. Human Immunology CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 79, 876\u2013882 (2018).","journal-title":"Hum Immunol."},{"key":"55239_CR74","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","volume":"12","author":"M Castella","year":"2018","unstructured":"Castella, M. et al. Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Molecular Therapy \u2013 Methods & Clinical Development. 12, 134\u2013144 (2018).","journal-title":"Molecular Therapy \u2013 Methods & Clinical Development."},{"key":"55239_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jviromet.2008.11.021","volume":"157","author":"H Kuroda","year":"2009","unstructured":"Kuroda, H., Kutner, R. H., Bazan, N. G. & Reiser, J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 157, 113\u201321 (2009).","journal-title":"J Virol Methods."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55239-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:11:06Z","timestamp":1671297066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55239-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55239"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55239-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18729"}}